Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania

被引:10
|
作者
Simons, Gwenda [1 ]
Veldwijk, Jorien [2 ,3 ,4 ]
Disantostefano, Rachael L. [5 ]
Englbrecht, Matthias
Radawski, Christine [6 ]
Bywall, Karin Scholin [7 ]
Mendez, Larissa Valor [8 ,9 ]
Hauber, Brett [10 ,11 ]
Raza, Karim [1 ,12 ,13 ,14 ]
Falahee, Marie [1 ]
机构
[1] Univ Birmingham, Coll Med & Dent Sci, Inst Inflammat & Ageing, Rheumatol Res Grp, Birmingham, W Midlands, England
[2] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Rotterdam, Netherlands
[3] Erasmus Univ, Erasmus Choice Modelling Ctr, Rotterdam, Netherlands
[4] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[5] Janssen R&D, Titusville, NJ USA
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
[7] Uppsala Univ, Ctr Res Eth & Bioeth, Uppsala, Sweden
[8] Friedrich Alexander Univ FAU Erlangen Nurnberg, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany
[9] Univ Klinikum Erlangen, Erlangen, Germany
[10] Pfizer Inc, New York, NY USA
[11] Univ Washington, Sch Pharm, Comparat Hlth Outcomes Policy & Econ Inst, Seattle, WA 98195 USA
[12] Univ Birmingham, Res Inflammatory Arthrit Ctr Versus Arthrit, Birmingham, W Midlands, England
[13] Univ Birmingham, MRC Versus Arthrit Ctr Musculoskeletal Ageing Res, Birmingham, W Midlands, England
[14] Sandwell & West Birmingham NHS Trust, Birmingham, W Midlands, England
基金
欧盟地平线“2020”;
关键词
RA; preventive treatment; patient preferences; discrete choice experiment; PERCEPTIONS;
D O I
10.1093/rheumatology/keac397
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To quantify preferences for preventive therapies for rheumatoid arthritis (RA) across three countries. Methods A web-based survey including a discrete choice experiment was administered to adults recruited via survey panels in the UK, Germany and Romania. Participants were asked to assume they were experiencing arthralgia and had a 60% chance of developing RA in the next 2 years and completed 15 choices between no treatment and two hypothetical preventive treatments. Treatments were defined by six attributes (effectiveness, risks and frequency/route of administration) with varying levels. Participants also completed a choice task with fixed profiles reflecting subjective estimates of candidate preventive treatments. Latent class models (LCMs) were conducted and the relative importance of attributes, benefit-risk trade-offs and predicted treatment uptake was subsequently calculated. Results Completed surveys from 2959 participants were included in the analysis. Most participants preferred treatment over no treatment and valued treatment effectiveness to reduce risk more than other attributes. A five-class LCM best fitted the data. Country, perceived risk of RA, health literacy and numeracy predicted class membership probability. Overall, the maximum acceptable risk for a 40% reduction in the chance of getting RA (60% to 20%) was 21.7%, 19.1% and 2.2% for mild side effects, serious infection and serious side effects, respectively. Predicted uptake of profiles reflecting candidate prevention therapies differed across classes. Conclusion Effective preventive pharmacological treatments for RA were acceptable to most participants. The relative importance of treatment attributes and likely uptake of fixed treatment profiles were predicted by participant characteristics.
引用
收藏
页码:596 / 605
页数:10
相关论文
共 50 条
  • [21] Treatment Preferences of Patients with Early Rheumatoid Arthritis: A Discrete-Choice Experiment
    Hazlewood, Glen S.
    Bombardier, Claire
    Tomlinson, George A.
    Thorne, Carter
    Bykerk, V. P.
    Thompson, Andrew
    Tin, Diane
    Marshall, Deborah
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [22] Patient Preferences for Biologic Agents in Rheumatoid Arthritis: A Discrete-Choice Experiment
    Augustovski, Federico
    Beratarrechea, Andrea
    Irazola, Vilma
    Rubinstein, Fernando
    Tesolin, Pablo
    Gonzalez, Juan
    Lencina, Veronica
    Scolnik, Marina
    Waimann, Christian
    Navarta, David
    Citera, Gustavo
    Soriano, Enrique R.
    VALUE IN HEALTH, 2013, 16 (02) : 385 - 393
  • [23] Treatment Preferences of Patients with Early Rheumatoid Arthritis: A Discrete-Choice Experiment
    Hazlewood, Glen
    Marshall, Deborah
    Tomlinson, George
    Thorne, Carter
    Thompson, Andrew
    Bykerk, Vivian
    Tin, Diane
    Bombardier, Claire
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (07) : 1265 - 1266
  • [24] Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment
    Hazlewood, Glen S.
    Bombardier, Claire
    Tomlinson, George
    Thorne, Carter
    Bykerk, Vivian P.
    Thompson, Andrew
    Tin, Diane
    Marshall, Deborah A.
    RHEUMATOLOGY, 2016, 55 (11) : 1959 - 1968
  • [25] DOG OWNERS PREFERENCES FOR PREVENTIVE ANTIPARASITIC TREATMENT FOR THEIR DOGS: A DISCRETE CHOICE EXPERIMENT (DCE) IN THE UK
    Deault, Rathwell D.
    Greaves, M.
    Hopkins, G.
    Aballea, S.
    Bebrysz, M.
    Wright, A.
    VALUE IN HEALTH, 2021, 24 : S238 - S238
  • [26] Preventing rheumatoid arthritis: Preferences for and predicted uptake of preventive treatments among high risk individuals
    Harrison, Mark
    Spooner, Luke
    Bansback, Nick
    Milbers, Katherine
    Koehn, Cheryl
    Shojania, Kam
    Finckh, Axel
    Hudson, Marie
    PLOS ONE, 2019, 14 (04):
  • [27] Doctors' preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment
    Kuijper, T. Martijn
    Folmer, Riette
    Stolk, Elly A.
    Hazes, Johanna M. W.
    Luime, Jolanda J.
    ARTHRITIS RESEARCH & THERAPY, 2017, 19
  • [28] Doctors’ preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment
    T. Martijn Kuijper
    Riëtte Folmer
    Elly A. Stolk
    Johanna M. W. Hazes
    Jolanda J. Luime
    Arthritis Research & Therapy, 19
  • [29] Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach
    Alten, Rieke
    Krueger, Klaus
    Rellecke, Julian
    Schiffner-Rohe, Julia
    Behmer, Olaf
    Schiffhorst, Guido
    Nolting, Hans-Dieter
    PATIENT PREFERENCE AND ADHERENCE, 2016, 10 : 2217 - 2228
  • [30] Patient Preferences for Biologic Treatments in Rheumatoid Arthritis
    Nafees, Beenish
    Lloyd, Andrew
    Gaich, Carol L.
    Birt, Julie
    Hughes, Rodney A.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S213 - S213